期刊文献+

强化极化液联合环磷腺干葡胺治疗慢性心衰的临床研究 被引量:5

Clinical effect of strengthened glucose-insulin-potassium solution combined with meglumine cyclic adenylate in treating patients with chronic heart failure
暂未订购
导出
摘要 目的探讨强化极化液联合环磷腺苷葡胺治疗慢性心衰的临床效果。方法将慢性心力衰竭患者96例,按治疗方法不同分为对照组(使用强化极化液)和观察组(强化极化液联合环磷腺苷葡胺)各48例,比较两组治疗总有效率、治疗前后心输出量及左心室射血分数。结果观察组显效18例,有效27例,无效3例,对照组显效11例,有效27例,无效10例,观察组治疗总有效率为93.75%(45/48),明显高于对照组79.17%(38/48)(P<0.05);治疗后,观察组平均心输出量及左心室射血分数均高于对照组(45/48),两组比较,差异均有统计学意义(P均<0.05)。结论环磷腺苷葡胺联合强化极化液治疗慢性心力衰竭能显著改善患者生命体征,缓解临床症状,疗效好,值得应用于临床。 Objective To explore the clinical effect of strengthened glucose-insulin-potassium solution (strengthened GIK) combined with meglumine cyclic adenylate (MCA) in the treatment of chronic heart failure. Methods Ninety-six patients with chronic heart failure admitted to our hospital were divided into control group (enhanced GIK) and observation group (GIK plus MCA). The total effective rate, cardiac output and left ventricular ejection fraction (LVEF) were compared between groups. Results In observation group, the numbers showing remarkable effect, effect, and no effect were 18, 27, and 3 respectively. In control group, the numbers showing remarkable effect, effect, and no effect were 11,27, and 10 respectively. The total effective rate in the observation group was 93.75%, significantly higher than that in the control group (79.17%), and so were the mean cardiac output and LVEF. Conclusion Strengthened GIK) combined with MCA in treating chronic heart failure, can significantly improve the vital signs, relieve symptoms, worthy of clinical application.
出处 《微创医学》 2015年第5期571-573,共3页 Journal of Minimally Invasive Medicine
基金 广西自然科学基金(编号:2012GXNSFAA053090)
关键词 慢性心力衰竭 强化极化液 环磷腺苷葡胺 临床疗效 Chronic heart failure Strengthened GIK Meglumine cyclic adenylate Clinical effect
  • 相关文献

参考文献15

二级参考文献96

  • 1王方正,张澍,黄德嘉,华伟,孙宝贵,沈法荣,吴书林,王建安,方全,吴立群,王景峰,王冬梅,郭涛,陈新,中华医学会心电生理和起搏分会心脏再同步治疗专家工作组.心脏再同步治疗慢性心力衰竭的建议[J].中华心律失常学杂志,2006,10(2):90-102. 被引量:91
  • 2徐继杰,刘斌,方卓,王楠,张荣昌.从慢性心力衰竭学说的发展认识和掌握其现代药物治疗观点[J].中国老年学杂志,2006,26(2):285-287. 被引量:14
  • 3Colucci WS. Molecular and cellular mechanisms of myocardial failure. Am J Cardiol, 1997, 80(11A) : 15L-25L
  • 4Braunwald E,Bristow MR Congestive heart failure: fifty years of progress. Circulation, 2000, 102(20 Suppl 4) : Ⅳ14-23.
  • 5Hunt SA, Abraham WT, Chin MH, et al. ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure) : developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Circulation, 2005, 112 (12) :e154-235.
  • 6Swedberg K, Cleland J, Dargie H, et al. Guidelines for the diagnosis and treatment of chronic heart failure: executive summary ( update 2005 ):The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. Eur Heart J, 2005, 26(11): 1115-1140.
  • 7Arnold JM, Liu P, Demers C, et al. Canadian Cardiovascular Society consensus conference recommendations on heart failure 2006 : diagnosis and management. Can J Cardiol, 2006, 22 (1): 23-45.
  • 8Heart Failure Society of America. HFSA 2006 Comprehensive Heart Failure Practice Guideline. J Card Fail, 2006, 12 ( 1 ) : e1-2.
  • 9Enright PL, Sherrill DL Reference equations for the six-minute walk in healthy adults. Am J Respir Crit Care Med, 1998, 158(5 pt 1) :1384-1387.
  • 10Troosters T, Gosselink R, Decramer M. Six minute walking distance in healthy elderly subjects. Eur Respir J, 1999, 14(2) : 270-274.

共引文献8398

同被引文献49

二级引证文献37

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部